Patents by Inventor Nicole HAUBST

Nicole HAUBST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20160158358
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Application
    Filed: September 11, 2015
    Publication date: June 9, 2016
    Inventors: Winfried ELIS, Seth ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Xizhong HUANG, Christian Carsten Silvester KUNZ, Elizabeth Anne REISINGER SPRAGUE, Qing SHENG
  • Antibodies for epidermal growth factor receptor 3 (HER3)
    Patent number: 9192663
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: November 24, 2015
    Assignee: NOVARTIS AG
    Inventors: Winfried Elis, Seth Ettenberg, Andrew Paul Garner, Nicole Haubst, Xizhong Huang, Christian Carsten Silvester Kunz, Elizabeth Anne Reisinger Sprague, Qing Sheng
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140308201
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140301946
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Antibodies for epidermal growth factor receptor 3 (HER3)
    Patent number: 8735551
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Andrew Paul Garner, Elizabeth Anne Reisinger Sprague, Seth Alexander Ettenberg, Christian Kunz, Nicole Haubst, Winfried Elis
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20130330324
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Application
    Filed: December 4, 2012
    Publication date: December 12, 2013
    Applicant: NOVARTIS AG
    Inventors: Winfried ELIS, Seth ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Xizhong HUANG, Christian Carsten Silvester KUNZ, Elizabeth Anne REISINGER SPRAGUE, Qing SHENG
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN III AND DOMAIN IV OF HER3
    Publication number: 20130251703
    Abstract: The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of HER3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof.
    Type: Application
    Filed: December 4, 2012
    Publication date: September 26, 2013
    Applicant: NOVARTIS AG
    Inventors: Winfried ELIS, Seth ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Heather Adkins HUET, Christian Carsten Silvester KUNZ, Elizabeth Anne REISINGER SPRAGUE, Qing SHENG
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20120107306
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Application
    Filed: August 22, 2011
    Publication date: May 3, 2012
    Applicant: NOVARTIS AG
    Inventors: Winfried ELIS, Seth ETTENGERG, Andrew Paul GARNER, Nicole HAUBST, Christian Carsten Silvester KUNZ, Elizabeth Anne Reisinger SPRAGUE